Compare Stocks

Comparative Price Performance Over Time

Compare Stocks - Price & Volume

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Adverum Biotechnologies, Inc. stock logo
ADVM
Adverum Biotechnologies
$9.30
-3.2%
$13.39
$7.40
$29.70
$193.04M0.89270,767 shs340,268 shs
Aerie Pharmaceuticals, Inc. stock logo
AERI
Aerie Pharmaceuticals
$15.25
$15.23
$4.81
$15.37
$753.61M-0.06974,748 shs600 shs
DBV Technologies S.A. stock logo
DBVT
DBV Technologies
$0.58
+1.8%
$0.74
$0.56
$2.37
$111.09M0.7353,146 shs91,106 shs
Krystal Biotech, Inc. stock logo
KRYS
Krystal Biotech
$154.76
-2.5%
$168.49
$86.03
$189.97
$4.42B0.91360,131 shs186,317 shs
Mesoblast Limited stock logo
MESO
Mesoblast
$7.36
+2.6%
$4.75
$1.61
$10.24
$840.35M3.451.62 million shs167,402 shs
The 10 Best AI Stocks to Own in 2024 Cover

Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.

Get This Free Report

Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Adverum Biotechnologies, Inc. stock logo
ADVM
Adverum Biotechnologies
-2.04%-3.90%-19.98%-44.45%+13.19%
Aerie Pharmaceuticals, Inc. stock logo
AERI
Aerie Pharmaceuticals
0.00%0.00%0.00%0.00%0.00%
DBV Technologies S.A. stock logo
DBVT
DBV Technologies
-14.85%-14.85%-22.28%-33.75%-65.42%
Krystal Biotech, Inc. stock logo
KRYS
Krystal Biotech
+0.67%-0.93%-11.70%+42.54%+76.14%
Mesoblast Limited stock logo
MESO
Mesoblast
-5.53%-1.65%+22.56%+293.96%-5.16%

MarketRank™

CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Adverum Biotechnologies, Inc. stock logo
ADVM
Adverum Biotechnologies
3.615 of 5 stars
3.51.00.04.83.10.80.0
Aerie Pharmaceuticals, Inc. stock logo
AERI
Aerie Pharmaceuticals
N/AN/AN/AN/AN/AN/AN/AN/A
DBV Technologies S.A. stock logo
DBVT
DBV Technologies
2.4901 of 5 stars
3.23.00.00.02.31.71.3
Krystal Biotech, Inc. stock logo
KRYS
Krystal Biotech
4.0783 of 5 stars
2.51.00.04.72.43.31.9
Mesoblast Limited stock logo
MESO
Mesoblast
2.1679 of 5 stars
3.15.00.00.01.70.80.6

Analyst Ratings

CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Adverum Biotechnologies, Inc. stock logo
ADVM
Adverum Biotechnologies
3.00
Buy$29.00211.83% Upside
Aerie Pharmaceuticals, Inc. stock logo
AERI
Aerie Pharmaceuticals
N/AN/AN/AN/A
DBV Technologies S.A. stock logo
DBVT
DBV Technologies
2.33
Hold$3.33478.70% Upside
Krystal Biotech, Inc. stock logo
KRYS
Krystal Biotech
3.00
Buy$171.0010.49% Upside
Mesoblast Limited stock logo
MESO
Mesoblast
2.17
Hold$13.6785.69% Upside

Current Analyst Ratings

Latest MESO, KRYS, DBVT, ADVM, and AERI Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
5/10/2024
Adverum Biotechnologies, Inc. stock logo
ADVM
Adverum Biotechnologies
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$30.00
5/8/2024
DBV Technologies S.A. stock logo
DBVT
DBV Technologies
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$10.00 ➝ $5.00
5/6/2024
Krystal Biotech, Inc. stock logo
KRYS
Krystal Biotech
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$200.00
4/30/2024
Adverum Biotechnologies, Inc. stock logo
ADVM
Adverum Biotechnologies
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageBuy$30.00
4/29/2024
Adverum Biotechnologies, Inc. stock logo
ADVM
Adverum Biotechnologies
Mizuho
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$40.00 ➝ $22.00
4/22/2024
Krystal Biotech, Inc. stock logo
KRYS
Krystal Biotech
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$200.00
4/16/2024
Krystal Biotech, Inc. stock logo
KRYS
Krystal Biotech
Stifel Nicolaus
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$178.00 ➝ $204.00
3/19/2024
Adverum Biotechnologies, Inc. stock logo
ADVM
Adverum Biotechnologies
Chardan Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$4.00
2/27/2024
Krystal Biotech, Inc. stock logo
KRYS
Krystal Biotech
Guggenheim
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$130.00 ➝ $175.00
2/27/2024
Krystal Biotech, Inc. stock logo
KRYS
Krystal Biotech
Citigroup
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$160.00 ➝ $195.00
2/27/2024
Krystal Biotech, Inc. stock logo
KRYS
Krystal Biotech
William Blair
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOutperform
(Data available from 5/10/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Sales & Book Value

CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Adverum Biotechnologies, Inc. stock logo
ADVM
Adverum Biotechnologies
$3.60M53.62N/AN/A$8.26 per share1.13
Aerie Pharmaceuticals, Inc. stock logo
AERI
Aerie Pharmaceuticals
$194.13M3.88N/AN/A($3.32) per share-4.59
DBV Technologies S.A. stock logo
DBVT
DBV Technologies
$15.73M7.06N/AN/A$0.73 per share0.79
Krystal Biotech, Inc. stock logo
KRYS
Krystal Biotech
$95.95M46.06N/AN/A$27.60 per share5.61
Mesoblast Limited stock logo
MESO
Mesoblast
$7.47M112.54N/AN/A$6.16 per share1.19

Profitability & Earnings

CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Adverum Biotechnologies, Inc. stock logo
ADVM
Adverum Biotechnologies
-$117.17M-$11.60N/AN/AN/AN/A-98.65%-52.85%8/8/2024 (Estimated)
Aerie Pharmaceuticals, Inc. stock logo
AERI
Aerie Pharmaceuticals
-$74.81M-$0.77N/AN/AN/A-17.09%N/A-2.00%N/A
DBV Technologies S.A. stock logo
DBVT
DBV Technologies
-$72.73M-$0.39N/AN/AN/A-461.32%-46.33%-35.32%7/29/2024 (Estimated)
Krystal Biotech, Inc. stock logo
KRYS
Krystal Biotech
$10.93M$1.871,934.7439.08N/AN/A-13.31%-12.61%8/5/2024 (Estimated)
Mesoblast Limited stock logo
MESO
Mesoblast
-$81.89M-$1.12N/AN/AN/AN/AN/AN/A5/23/2024 (Estimated)

Latest MESO, KRYS, DBVT, ADVM, and AERI Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/6/2024Q1 2024
Krystal Biotech, Inc. stock logo
KRYS
Krystal Biotech
$0.20$0.03-$0.17$0.03$47.37 million$45.25 million      
3/18/2024Q4 2023
Adverum Biotechnologies, Inc. stock logo
ADVM
Adverum Biotechnologies
-$2.80-$2.30+$0.50-$2.30N/AN/A
3/7/2024Q4 2023
DBV Technologies S.A. stock logo
DBVT
DBV Technologies
-$0.16-$0.06+$0.10-$0.06$1.10 million$8.88 million    
2/26/202412/31/2023
Krystal Biotech, Inc. stock logo
KRYS
Krystal Biotech
-$0.52$0.30+$0.82$0.30$27.43 million$42.14 million      

Dividends

CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Adverum Biotechnologies, Inc. stock logo
ADVM
Adverum Biotechnologies
N/AN/AN/AN/AN/A
Aerie Pharmaceuticals, Inc. stock logo
AERI
Aerie Pharmaceuticals
N/AN/AN/AN/AN/A
DBV Technologies S.A. stock logo
DBVT
DBV Technologies
N/AN/AN/AN/AN/A
Krystal Biotech, Inc. stock logo
KRYS
Krystal Biotech
N/AN/AN/AN/AN/A
Mesoblast Limited stock logo
MESO
Mesoblast
N/AN/AN/AN/AN/A

Debt

CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Adverum Biotechnologies, Inc. stock logo
ADVM
Adverum Biotechnologies
N/A
4.13
4.13
Aerie Pharmaceuticals, Inc. stock logo
AERI
Aerie Pharmaceuticals
N/A
2.27
1.92
DBV Technologies S.A. stock logo
DBVT
DBV Technologies
N/A
4.26
4.26
Krystal Biotech, Inc. stock logo
KRYS
Krystal Biotech
N/A
17.76
17.55
Mesoblast Limited stock logo
MESO
Mesoblast
0.21
2.71
N/A

Ownership

Institutional Ownership

CompanyInstitutional Ownership
Adverum Biotechnologies, Inc. stock logo
ADVM
Adverum Biotechnologies
48.17%
Aerie Pharmaceuticals, Inc. stock logo
AERI
Aerie Pharmaceuticals
95.94%
DBV Technologies S.A. stock logo
DBVT
DBV Technologies
71.74%
Krystal Biotech, Inc. stock logo
KRYS
Krystal Biotech
86.29%
Mesoblast Limited stock logo
MESO
Mesoblast
1.43%

Miscellaneous

CompanyEmployeesShares OutstandingFree FloatOptionable
Adverum Biotechnologies, Inc. stock logo
ADVM
Adverum Biotechnologies
12120.76 million19.89 millionOptionable
Aerie Pharmaceuticals, Inc. stock logo
AERI
Aerie Pharmaceuticals
37649.42 million47.22 millionOptionable
DBV Technologies S.A. stock logo
DBVT
DBV Technologies
104192.87 million191.71 millionOptionable
Krystal Biotech, Inc. stock logo
KRYS
Krystal Biotech
22928.56 million24.49 millionOptionable
Mesoblast Limited stock logo
MESO
Mesoblast
83114.18 million92.71 millionOptionable

AERI, DBVT, ADVM, KRYS, and MESO Headlines

SourceHeadline
Mesoblast (NASDAQ:MESO) Trading Down 7.9%Mesoblast (NASDAQ:MESO) Trading Down 7.9%
marketbeat.com - May 8 at 3:56 PM
Mesoblast (NASDAQ:MESO) Lowered to Sell at StockNews.comMesoblast (NASDAQ:MESO) Lowered to Sell at StockNews.com
americanbankingnews.com - May 8 at 3:56 AM
Mesoblast Limited (NASDAQ:MESO) Receives Consensus Rating of "Hold" from AnalystsMesoblast Limited (NASDAQ:MESO) Receives Consensus Rating of "Hold" from Analysts
americanbankingnews.com - May 7 at 1:30 AM
If you invested $8,000 in Mesoblast shares at the beginning of 2024, guess how much youd have now!If you invested $8,000 in Mesoblast shares at the beginning of 2024, guess how much you'd have now!
msn.com - May 3 at 1:43 AM
ASX 200 closes down 1.23 per cent on WednesdayASX 200 closes down 1.23 per cent on Wednesday
msn.com - May 2 at 3:43 PM
Mesoblast (NASDAQ:MESO) Stock Price Up 10.2%Mesoblast (NASDAQ:MESO) Stock Price Up 10.2%
marketbeat.com - May 1 at 1:22 PM
Australia stocks lower at close of trade; S&P/ASX 200 down 1.23%Australia stocks lower at close of trade; S&P/ASX 200 down 1.23%
msn.com - May 1 at 8:52 AM
Mesoblast (NASDAQ:MESO) Upgraded to Hold at StockNews.comMesoblast (NASDAQ:MESO) Upgraded to Hold at StockNews.com
americanbankingnews.com - May 1 at 4:26 AM
StockNews.com Upgrades Mesoblast (NASDAQ:MESO) to "Hold"StockNews.com Upgrades Mesoblast (NASDAQ:MESO) to "Hold"
marketbeat.com - April 30 at 11:06 PM
Mesoblast (NASDAQ:MESO) Shares Gap Down to $7.10Mesoblast (NASDAQ:MESO) Shares Gap Down to $7.10
marketbeat.com - April 30 at 1:06 PM
Yen falls after suspected intervention on Monday, eyes on FedYen falls after suspected intervention on Monday, eyes on Fed
msn.com - April 30 at 11:08 AM
Why is the Mesoblast share price taking a dive on Tuesday?Why is the Mesoblast share price taking a dive on Tuesday?
msn.com - April 30 at 12:43 AM
Appendix 4c Quarterly Activity Report for Quarter Ended March 31, 2024Appendix 4c Quarterly Activity Report for Quarter Ended March 31, 2024
globenewswire.com - April 29 at 9:05 PM
Soft landing remains within reach as consumer spending spree set for breather: UBSSoft landing remains within reach as consumer spending spree set for breather: UBS
msn.com - April 29 at 7:42 PM
Stablecoin Tether is losing market share - reportStablecoin Tether is losing market share - report
msn.com - April 29 at 7:42 PM
US Dollar Uptrend on Thin Ice as Fed Takes Center Stage This WeekUS Dollar Uptrend on Thin Ice as Fed Takes Center Stage This Week
msn.com - April 29 at 2:42 PM
Mesoblast (NASDAQ:MESO) Shares Gap Up to $6.24Mesoblast (NASDAQ:MESO) Shares Gap Up to $6.24
marketbeat.com - April 29 at 12:11 PM
Mesoblast (NASDAQ:MESO) Trading Up 9.4%Mesoblast (NASDAQ:MESO) Trading Up 9.4%
marketbeat.com - April 23 at 1:23 PM
Mesoblast (NASDAQ:MESO) Shares Gap Up to $5.21Mesoblast (NASDAQ:MESO) Shares Gap Up to $5.21
marketbeat.com - April 22 at 12:49 PM
Mesoblast (NASDAQ:MESO) Stock Price Up 7.9%Mesoblast (NASDAQ:MESO) Stock Price Up 7.9%
marketbeat.com - April 17 at 12:20 PM
Insiders are buying Mesoblast and these ASX sharesInsiders are buying Mesoblast and these ASX shares
msn.com - April 16 at 9:41 AM
Mesoblast Limited (NASDAQ:MESO) Given Consensus Recommendation of "Hold" by BrokeragesMesoblast Limited (NASDAQ:MESO) Given Consensus Recommendation of "Hold" by Brokerages
marketbeat.com - April 12 at 2:17 AM
Mesoblast Limited (NASDAQ:MESO) Sees Large Growth in Short InterestMesoblast Limited (NASDAQ:MESO) Sees Large Growth in Short Interest
marketbeat.com - April 12 at 12:14 AM
Mesoblast Limited: Back From The DeadMesoblast Limited: Back From The Dead
seekingalpha.com - April 10 at 1:29 PM

New MarketBeat Followers Over Time

Media Sentiment Over Time

Company Descriptions

Adverum Biotechnologies logo

Adverum Biotechnologies

NASDAQ:ADVM
Adverum Biotechnologies, Inc., a clinical-stage company, develops gene therapy product candidates to treat ocular diseases. Its lead product candidate is ixoberogene soroparvovec (ADVM-022), a single intravitreal injection gene therapy candidate used for the treatment of patients with wet age-related macular degeneration and diabetic macular edema which is in phase 2 clinical trials. The company is developing ADVM-062 (AAV.7m8-L-opsin), a novel gene therapy product candidate for the treatment of blue cone monochromacy via a single IVT injection. Adverum Biotechnologies, Inc. has license and collaboration agreements with University of California; GenSight Biologics; Lexeo Therapeutics; and Virovek, Inc. The company was formerly known as Avalanche Biotechnologies, Inc. and changed its name to Adverum Biotechnologies, Inc. in May 2016. Adverum Biotechnologies, Inc. was incorporated in 2006 and is headquartered in Redwood City, California.
Aerie Pharmaceuticals logo

Aerie Pharmaceuticals

NASDAQ:AERI
Aerie Pharmaceuticals, Inc., a pharmaceutical company, focuses on the discovery, development, and commercialization of ophthalmic therapies for open-angle glaucoma, dry eye, diabetic macular edema, and wet age-related macular degeneration in the United States. Its products include Rhopressa, a once-daily eye drop to reduce elevated intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension; and Rocklatan, a once-daily fixed-dose combination of Rhopressa and latanopros to reduce IOP to treat patients with open-angle glaucoma or ocular hypertension. The company also develops AR-15512 to treat signs and symptoms of dry eye; and AR-1105 and AR-14034 SR sustained-release implants focused on retinal diseases. It has a collaborative research, development, and licensing agreement with DSM Biomedical. Aerie Pharmaceuticals, Inc. was incorporated in 2005 and is headquartered in Durham, North Carolina.
DBV Technologies logo

DBV Technologies

NASDAQ:DBVT
DBV Technologies S.A., a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. Its product pipeline comprising Viaskin Peanut, an immunotherapy product, which has completed Phase 3 clinical trial for the treatment of peanut allergies; and Viaskin Milk which is in Phase 1/2 clinical trial for the treatment of immunoglobulin E (IgE) mediated or cow's milk protein allergy and eosinophilic esophagitis. The company's earlier stage research programs include vaccine for the respiratory syncytial virus, potential treatments for inflammatory bowel disease, celiac disease, and type I diabetes. In addition, it develops Viaskin technology platform, a platform to potentially treat food allergy. The company has a collaboration with Nestlé Health Science to develop MAG1C, a ready-to-use atopy patch test for the diagnosis of non-IgE mediated CMPA in infants and toddlers. DBV Technologies S.A. was incorporated in 2002 and is headquartered in Montrouge, France.
Krystal Biotech logo

Krystal Biotech

NASDAQ:KRYS
Krystal Biotech, Inc., a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB). The company also develops KB105, which is in Phase 1/2 clinical trials for treating patients with deficient autosomal recessive congenital ichthyosis; KB104 for treating netherton syndrome; KB407 that is in Phase 1 clinical trials for treating cystic fibrosis; KB707 that is in Phase 1 clinical trials for the treatment of anti-PD-1 relapsed/refractory; KB408, which is in Phase 1 clinical trials for treating Alpha-1 antitrypsin deficiency; and KB301 that is in Phase 2 clinical trials for treating aesthetic skin conditions, as well as in open label study with ophthalmic B-VEC for treating for ocular complications of deb. Krystal Biotech, Inc. was founded in 2016 and is headquartered in Pittsburgh, Pennsylvania.
Mesoblast logo

Mesoblast

NASDAQ:MESO
Mesoblast Limited engages in the development of regenerative medicine products in Australia, the United States, Singapore, and Switzerland. The company offers products in the areas of cardiovascular, spine orthopedic disorder, oncology, hematology, and immune-mediated and inflammatory diseases. Its proprietary regenerative medicine technology platform is based on specialized cells known as mesenchymal lineage cells. The company offers Remestemcel-L that is in Phase III clinical trials for the treatment of systemic inflammatory diseases, including steroid refractory acute graft versus host disease, acute respiratory distress syndrome, and biologic refractory inflammatory bowel disease; and Remestemcel-L, which is in Phase III clinical trials to treat chronic heart failure and chronic low back pain due to degenerative disc disease. It is also developing MPC-300-IV to treat biologic refractory rheumatoid arthritis diabetic nephropathy; and MPC-25-IC for the treatment or prevention of acute myocardial infarction. It has strategic partnerships with Tasly Pharmaceutical Group to offer MPC-150-IM for heart failure and MPC-25-IC for heart attacks in China; JCR Pharmaceuticals Co. Ltd. to treat wound healing in patients with epidermolysis bullosa; and Grünenthal to develops and commercializes cell therapy for the treatment of chronic low back pain. The company was incorporated in 2004 and is headquartered in Melbourne, Australia.